ATLAS: A phase 3 trial evaluating the efficacy of apalutamide (ARN-509) in patients with high-risk localized or locally advanced prostate cancer receiving primary radiation therapy

被引：2

作者：

Bossi, A. ^{[1
]}

Dearnaley, D. ^{[2
,3
]}

McKenzie, M. ^{[4
]}

Baskin-Bey, E. ^{[5
]}

Tyler, R. ^{[5
]}

Tombal, B. ^{[6
]}

Freedland, S. J. ^{[7
]}

Roach, M., III ^{[8
]}

Widmark, A. ^{[9
]}

Dicker, A. P. ^{[10
]}

Wiegel, T. ^{[11
]}

Shore, N. ^{[12
]}

Smith, M. ^{[13
,14
]}

Yu, M. ^{[5
]}

Kheoh, T. ^{[15
]}

Thomas, S. ^{[16
]}

Sandler, H. M. ^{[17
]}

机构：

[1] Inst Gustave Roussy, Radiat Oncol, Villejuif, France

[2] Inst Canc Res, Acad Radiotherapy, London, England

[3] Royal Marsden Hosp, London, England

[4] British Columbia Canc Agcy, Med Oncol, Vancouver, BC, Canada

[5] Janssen Res & Dev, WC Clin Oncol, Los Angeles, CA USA

[6] Clin Univ St Luc, Urol, Brussels, Belgium

[7] Cedars Sinai Med Ctr, Surg, Los Angeles, CA 90048 USA

[8] Univ Calif San Francisco, Radiat Oncol, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA

[9] Umea Univ, Radiat Sci, Umea, Sweden

[10] Thomas Jefferson Univ, Radiat Oncol, Philadelphia, PA 19107 USA

[11] Ulm Med Univ, Radiat Oncol, Ulm, Germany

[12] Carolina Urol Res Ctr, Urol, Myrtle Beach, SC USA

[13] Massachusetts Gen Hosp, Ctr Canc, Hematol Oncol, Boston, MA USA

[14] Harvard Med Sch, Boston, MA USA

[15] Janssen Res & Dev, Clin Biostat, San Diego, CA USA

[16] Janssen Pharmaceut, Oncol Translat Res, Spring House, PA USA

[17] Cedars Sinai Med Ctr, Radiat Oncol, Los Angeles, CA 90048 USA

来源：

ANNALS OF ONCOLOGY | 2016年 / 27卷

关键词：

D O I：

10.1093/annonc/mdw372.52

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

769TiP

引用

页数：1

共 50 条

[1] ATLAS: A randomized, double-blind, placebo controlled, phase 3 trial of apalutamide (ARN-509) in patients with high-risk localized or locally advanced prostate cancer receiving primary radiation therapy.
Sandler, Howard M.
McKenzi, Michael R.
Tombal, Bertrand F.
Baskin-Bey, Edwina
Freedland, Stephen J.
Roach, Mack
Widmark, Anders
Bossi, Alberto
Dicker, Adam
Wiegel, Thomas
Shore, Neal D.
Smith, Matthew Raymond
Yu, Margaret K.
Kheoh, Thian
Thomas, Shibu
Dearnaley, David P.
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[2] Neoadjuvant apalutamide (ARN-509) and radical prostatectomy in treatment of intermediate to high risk prostate cancer (NEAR) phase II trial
Yang, Xinyan
Aslim, Edwin Jonathan
Ngo, Nye Thane
Khor, Li Yan
Chong, Tsung Wen
Yuen, John Shyi Peng
Tay, Kae Jack
Ho, Henry Sun Sien
Lee, Lui Shiong
INTERNATIONAL JOURNAL OF UROLOGY, 2020, 27 : 55 - 55
[3] NEOADJUVANT APALUTAMIDE (ARN-509) AND RADICAL PROSTATECTOMY IN TREATMENT OF INTERMEDIATE TO HIGH RISK PROSTATE CANCER (NEAR) PHASE II TRIAL
Yang, XinYan
Aslim, Edwin Jonathan
Nye Thane Ngo
Khor, Li Yan
Chong, Tsung Wen
Yuen, John Shyi Peng
Tay, Kae Jack
Ho, Henry Sun Sien
Lee, Lui Shiong
JOURNAL OF UROLOGY, 2020, 203 : E1216 - E1217
[4] Patient-reported outcomes of a phase II neoadjuvant apalutamide (ARN-509) and radical prostatectomy in treatment of intermediate- to high-risk prostate cancer (NEAR) trial
Yang, Xinyan
Allen, John Carson
Aslim, Edwin Jonathan
Tay, Kae Jack
Yuen, Shyi Peng John
Kanesvaran, Ravindran
Chua, Melvin Lee Kiang
Chong, Tsung Wen
Ho, Sun Sien Henry
Lee, Lui Shiong
INTERNATIONAL JOURNAL OF UROLOGY, 2022, 29 (11) : 1322 - 1330
[5] Neoadjuvant apalutamide (ARN-509) and radical prostatectomy in treatment of intermediate to high risk prostate cancer (NEAR) phase II trial - initial oncological outcomes
Yang, X.
Aslim, E. J.
Ngo, N. T.
Khor, L. Y.
Chong, T. W.
Yuen, J. S. P.
Tay, K. J.
Ho, H. S. S.
Lee, L. S.
BJU INTERNATIONAL, 2019, 123 : 40 - 40
[6] Patient-reported outcomes of neoadjuvant apalutamide (ARN-509) and radical prostatectomy in treatment of intermediate to high risk prostate cancer (NEAR) trial - a phase II trial
Yang, Xinyan
Aslim, Edwin Jonathan
Chong, Tsung Wen
Yuen, John Shyi Peng
Tay, Kae Jack
Ho, Henry Sun Sien
Lee, Lui Shiong
INTERNATIONAL JOURNAL OF UROLOGY, 2020, 27 : 55 - 56
[7] Editorial comments on Patient-reported outcomes of a phase II neoadjuvant Apalutamide (ARN-509) and radical prostatectomy in treatment of intermediate- to high-risk prostate cancer (NEAR) trial
Kato, Manabu
INTERNATIONAL JOURNAL OF UROLOGY, 2022, 29 (11) : 1330 - 1330
[8] Phase 2 Study of the Safety and Antitumor Activity of Apalutamide (ARN-509), a Potent Androgen Receptor Antagonist, in the High-risk Nonmetastatic Castration-resistant Prostate Cancer Cohort
Smith, Matthew R.
Antonarakis, Emmanuel S.
Ryan, Charles J.
Berry, William R.
Shore, Neal D.
Liu, Glenn
Alumkal, Joshi J.
Higano, Celestia S.
Maneval, Edna Chow
Bandekar, Rajesh
de Boer, Carla J.
Yu, Margaret K.
Rathkopf, Dana E.
EUROPEAN UROLOGY, 2016, 70 (06) : 963 - 970
[9] Phase III Study for local or locally advanced Prostate Cancer: Randomized, double-blind, Placebo-controlled Phase 3 Study of Apalutamide in Patients with local High-Risk Prostate Cancer or locally advanced Prostate Cancer receiving primary Radiotherapy (ATLAS) - Study AP 90/15 of the AUO
Rexer, H.
Graefen, M.
Grimm, M. -O.
AKTUELLE UROLOGIE, 2017, 48 (06) : 520 - +
[10] The management of high-risk, locally advanced, prostate cancer radiation therapy
Sridharan, Swetha
Warde, Padraig
CUAJ-CANADIAN UROLOGICAL ASSOCIATION JOURNAL, 2012, 6 (05): : 393 - 395

← 1 2 3 4 5 →